SCHEMBL24358293

SCHEMBL24358293

CC(C)NCCCCNC(=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGS1 P23219 7/20 0.40
PTGS2 P35354 7/20 0.40
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
MGLL Q99685 4/20 0.38
FAAH O00519 3/20 0.38
TP53 P04637 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
HSP90AA1 P07900 1/20 0.37
TLR9 Q9NR96 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20864144 0.89 PTGS1 (0.44) PTGS1PTGS2OPRM1OPRD1OPRK1
SCHEMBL18995821 0.86 PTGS1 (0.51) PTGS1PTGS2MGLLFAAHTP53
SCHEMBL12401794 0.86 MEN1 (0.43) POLBHSD17B10PTGS1PTGS2OPRM1
SCHEMBL17175252 0.86 NAMPT (0.43) POLBHSD17B10PTGS1PTGS2OPRM1
SCHEMBL14984835 0.85 PTGS1 (0.49) POLBHSD17B10PTGS1PTGS2MGLL
SCHEMBL14868081 0.84 NAMPT (0.44) POLBHSD17B10PTGS1PTGS2OPRM1
SCHEMBL12641968 0.84 LMNA (0.43) POLBHSD17B10PTGS1PTGS2MGLL
SCHEMBL22214462 0.84 PTGS1 (0.42) POLBHSD17B10PTGS1PTGS2OPRM1
SCHEMBL14240811 0.84 MGLL (0.54) HSD17B10PTGS1PTGS2MGLLFAAH
SCHEMBL12132672 0.82 PTGS1 (0.57) PTGS1PTGS2MGLLFAAHTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263896-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF VITALIXIR (BEIJING) CO., LTD (CN) 2023-08-24 US disclosed
US-20230263896-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF VITALIXIR (BEIJING) CO., LTD (CN) 2023-08-24 US disclosed
US-20220127323-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF VITALIXIR (BEIJING) CO., LTD (CN) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127323-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF VIP, IAPP, LNPEP POLB 4169/4885HSD17B10 4095/4885PTGS1 3231/4885
US-20230263896-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF VIP, IAPP, LNPEP POLB 4033/4885HSD17B10 3964/4885PTGS1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.